Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,38
KB-1,24
PKN109,35106,2-0,05
Msft2,55
IBM-0,97
DCX70,9570,980,17
PFE2,03
16.12.2017 2:10:00
Indexy online
AD Index online
select
AD Index online
 

  • 15.12.2017
Spotlight (US Other OTC (Pink Sheets))
Závěr k 15.12.2017 Změna (%) Změna (USD) Objem obchodů (ks)
0,239 0,00 0,00 6 391
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 16.12.2017
Popis společnosti
Obecné informace
Název společnostiSpotlight Innovation Inc
TickerSTLT
Kmenové akcie:Ordinary Shares
RICSTLT.PK
ISINUS8492071050
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.9.2017
Počet zaměstnanců k 31.12.2012 0
Akcie v oběhu k 15.11.2017 34 290 934
MěnaUSD
Kontaktní informace
Ulice11147 Aurora Ave Bldg 3
MěstoURBANDALE
PSČ50322-7904
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon15 152 749 087

Business Summary: Spotlight Innovation Inc. is a pharmaceutical company. The Company is focused on acquiring the intellectual property rights to therapeutics designed to address unmet medical needs. As of June 30, 2017, the Company had four subsidiaries: Celtic Biotech Iowa, Inc. (Celtic Iowa), Caretta Therapeutics, LLC (Caretta), SMA Therapeutics, LLC (SMA), and Zika Therapeutics, LLC (Zika). It is focused on various diseases, including cancer, pain management, Zika Virus infection and spinal muscular atrophy. The Company, through Celtic Iowa, holds interest in Celtic Biotech Limited, which is engaged in developing specialized compounds derived from snake venom, for the treatment of solid cancers and cancer imaging. The Company, through Caretta, is focused on developing the commercialization of over-the-counter products. It is also engaged in discovery, synthetic modification, and preclinical validation of drug-like compounds intended to treat patients with Zika virus infection.
Financial Summary: BRIEF: For the nine months ended 30 September 2017, Spotlight Innovation Inc revenues increased from $0K to $1K. Net loss before extraordinary items increased 22% to $5.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development expense increase from $182K to $685K (expense), Interest expense increase of 100% to $997K (expense).
Odvětvová klasifikace
TRBC2009Oil / Gas Exploration / Production
TRBC2012Bio Therapeutic Drugs
RBSS2004Oil & Gas Exploration & Production
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICOil And Gas Field Services, Nec
SICCommercial Physical Research



  • Poslední aktualizace: 16.12.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Interim Chief Executive Officer, Chief Operating OfficerJohn Krohn-23.5.201728.12.2016
Chief Financial OfficerJohn Pim626.11.20156.11.2015